AstraZeneca PLC published more pivotal research data for its Covid-19 vaccine and said the injection was 76% effective in preventing Covid-19 with symptoms in a more complete analysis of the study results than the company previously provided.
AstraZeneca said its latest vaccine efficacy figure was based on an analysis of 190 cases of symptomatic Covid-19 in the trial, 49 more cases than the company had previously analyzed.
Despite the additional cases, the performance of the vaccine was in line with what AstraZeneca reported first.
The London-based drug company had started fire earlier this week after it provided preliminary data from the trial showing that its vaccine was 79% effective in 141 subjects.
An independent study committee said the data was outdated, prompting the U.S. National Institute of Allergy and Infectious Diseases to issue an unusual statement highlighting the experts’ concerns.